Directory · FR
Biotechnology Research in France
A register of firms and the professionals working at them in the Biotechnology Research sector based in France. Browse the public index, then filter or export on Kipplo.
Companies
1.4K on file
Biosynex Pharma
BIOSYNEX conçoit, fabrique et commercialise des solutions de diagnostic rapide pour une santé accessible, préventive et personnalisée. Le groupe développe également des marques à forte notoriété dans l’univers du bien-être et de la santé, telles qu’INNOXA, experte du soin oculaire et dermo-cosmétique, et PARAKITO, spécialiste des solutions anti-nuisibles. Fondé en 2005, le groupe vend ses produits et solutions en France et dans plus de 90 pays dans le monde entier.
501 to 1000 staff
Valneva
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines, including the world’s first and only chikungunya vaccine, as well as certain third-party vaccines. Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the U.S. with approximately 700 employees.
501 to 1000 staff
Afyren
AFYREN is a pioneering biotech company, developing innovative solutions for the production of high value-added biobased compounds. Our purpose is to “enable low-carbon, circular industry by providing biobased solutions built with our partners to benefit the environment”. Our Technology is based on a biomimetic fermentation process patented worldwide through 10 patent families Our production model: AFYREN NEOXY, AFYREN’s first plant is a unique, low-carbon, zero-waste biorefinery that produces 7 100% biobased acids. It is located in Carling Saint-Avold (Grand-Est region, France) a strategic location set in the heart of Europe close to the major players in our markets and close to our suppliers of biomass coproducts. This approach enable us short-circuit production. Our markets: Our solutions find applications in a variety of industrial sectors, such as food, cosmetics, pharmaceuticals, chemicals and materials. We collaborate with international partners to develop innovative, sustainable products that meet market needs. Commitment to sustainability: At AFYREN, we are committed to minimizing our environmental footprint while maximizing our social and economic impact. We firmly believe in the need to reconciles economic performance with environmental responsibility to ensure a better future for generations to come. Join us in our mission to reinvent the chemical industry through bioeconomy and sustainable innovation!
51 to 200 staff
Cilcare
CILCARE is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. We believe hearing acts as a valuable indicator of our health and must be monitored and preserved accordingly. As awareness of the link between hearing and chronic health conditions grows, auditory sciences are paving the way for the early detection of chronic neurocognitive, inflammatory, and age-related diseases. CILCARE External Innovation supports its partners in the health and life-sciences sector in the development of new therapies to prevent and treat auditory-related diseases including inherited hearing loss, synaptopathy, ototoxicity, sensorineural hearing loss and tinnitus. CILCARE Therapeutics has forged a portfolio of proprietary drug candidates and co-developed programs, while pioneering an unprecedented clinical approach to developing compounds targeting cochlear synaptopathy. CILCARE Auditory Analytics aims to position hearing as a key asset of preventive medicine and global healthcare monitoring. We aim to utilize patients' auditory measurements to define digital auditory signatures that will serve to characterize different forms of hearing impairments or other pathologies with precision.
51 to 200 staff
Discngine
Discngine is a leading developer and provider of scientific software for Life Science Research organizations. Founded in 2004 and based in Paris, Discngine is dedicated to enhancing the discovery of new molecules. Its in-house developed SaaS applications and tailored IT solutions support R&D divisions across the pharmaceutical, cosmetics, and agro-sciences industries worldwide. Discngine’s expertise spans cheminformatics, structural bioinformatics, lab informatics, and data science. Coupled with in-depth knowledge of molecular modeling and simulation, as well as experimental data acquisition and management, Discngine delivers cloud-based applications that comply with ISO-27001 information security management standards. Discngine has over 75 employees worldwide and recently shifted to a distributed model. Thanks to its strong company culture and innovative management, Discngine offers a friendly and exciting working environment to everyone who wants to join the company!
51 to 200 staff
Imv Technologies
World Leader in Animal Reproduction and Ultrasound scanners for Farm Animals. IMV Technologies designs, manufactures, and distributes reproductive solutions needed by breeders, insemination centers, vets, academy to help them improve their herds. Watch more: https://youtu.be/k5hnlv6qBwE Why join the IMV Technologies Group? Make A Difference We, as an organisation, contribute to feeding the world population and we support our customer to do this in an efficient and sustainable way. In our business we also supply technology that strives to improve animal care. On an individual level, at IMV you can see the impact of your work and you can really have influence within the organisation. Be part of our Innovation culture At IMV, innovation is more than one of our core values, it is in our DNA. Whether that be setting the industry standard with the insemination straw or with breakthrough technology in our wireless ultrasound scanners. It is our global vision to be the most innovative leader in multi-species assisted reproduction and animal diagnostic imaging. This means we are looking for people who are naturally curious and who are prepared to challenge the status quo, to join our team. A People-focused organisation At IMV we care about our people. We recognise our people are our number one asset. We are proud to have a passionate team and we value everyone’s input. With us, you are treated as a person, never as a number and you can access people at all levels of the organisation. Here, you will be given the autonomy to really drive your role with the support of your manager and colleagues. Gain international exposure IMV is a truly global organisation, while still being mid-size. This means many of our colleagues have daily opportunities to collaborate with people around the world, whether that’s fellow colleagues, customers or one of our external partners.
201 to 500 staff
Invivoscribe
Invivoscribe® is a global leader dedicated to Improving Lives with Precision Diagnostics®, advancing the quality of healthcare by providing innovative products and clinical services for oncology. Our Streamlined CDx® (companion diagnostic) model accelerates the development of novel therapeutics, enabling personalized approaches to patient care. With products manufactured in our state-of-the-art cGMP facility, we provide a comprehensive range of platform agnostic assays, reagents, controls and software for clonal gene rearrangements, translocations, gene mutation testing, and measurable residual disease (MRD). Invivoscribe’s products consistently surpass industry and regulatory standards and play a crucial role in identifying, stratifying and monitoring hematologic cancers, enabling scientific advancements and empowering clinicians to make informed treatment decisions. Our subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM®), offers extensive clinical diagnostic and biopharma services for the detection and monitoring of myelo- and lymphoproliferative disorders. The LabPMM network performs globally standardized flow cytometry and molecular testing services for pharmaceutical and healthcare organizations, providing results that are critically important for patient care in the U.S, Europe, and Asia. Join us in our mission to revolutionize oncology diagnostics and improve patient outcomes worldwide. Visit our website to discover how Invivoscribe’s ecosystem is driving advancements in precision medicine.
201 to 500 staff
Novalix
Novalix is a premier drug discovery partner to biotech firms and pharmaceutical companies. We apply our exceptional scientific talent and exclusive resources across our platforms to improve the odds of success at each critical pre-clinical stage. The better the science, the better the outcomes. For additional information visit
201 to 500 staff
Treefrog Therapeutics
TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients. TreeFrog Therapeutics is developing a pipeline of therapeutic candidates using proprietary C-Stem technology, allowing for the mass production of induced pluripotent stem cells and their differentiation into ready-to-transplant microtissues with unprecedented scalability and cell quality. Bringing together over 150 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M in 2021 to advance its pipeline of stem cell-based therapies in the field of regenerative medicine with the lead program in Parkinson's Disease. In 2022, the company opened a technological hub in Boston, USA to drive the adoption of C-Stem and initiate co-development partnerships with leading academic, biotech and industry players in the field of cell therapy.
51 to 200 staff
Abyss Ingredients
Abyss Ingredients was founded in 2004 on the initiative of Brittany's fishing and fish processing professionnals who aimed at valuate marine by-products. Our R&D team works together with universities and CRO on innovation and new developments to respond to the growing demand of natural and sustainable healthy-aging solutions. The efficacy of our ingredients is scientifically proven: we heavily invest in studies to bring to our clients full solution.
11 to 50 staff
Genoway
Since genOway aims at bridging the gap between preclinical findings and clinical success with advanced, genetically engineered preclinical models and solutions. From customized mice and rats to ready-to-use cell lines, our solutions provide increased predictability and accelerate therapeutic breakthroughs. We work with 17 of the world’s Top pharma companies—as well as leading biotech firms, CROs, and academic institutions. At the heart of genOway is a team of 150+ skilled professionals, from 17 nationalities, all committed to advancing preclinical research. What We Offer • A catalogue of validated, ready-to-use mice and cell lines—developed in partnership with biopharma leaders • Custom-made models tailored to specific research goals • Proof-of-concept experiments aligned with model design and project needs What Makes Us Unique • Scientific Excellence: Our models have contributed to peer-reviewed publications and IND approvals. • Easy access to the models: High-health-status models sourced from certified breeders in the US and Europe • Strong Collaborations: Models co-validated with pharma and biotech partners • Full Freedom to Operate: Secure use of technologies with guaranteed FTO in the specific field Our Commitment to Sustainability Through the genOway Low-Carbon Project, launched in 2021, we’ve committed to reducing our greenhouse gas emissions by 6% annually over a period of 5 years, by rethinking lab operations, logistics, and energy use. We’re proud to report that this initiative has already delivered measurable results, putting us on track to meet our reduction targets.
51 to 200 staff
I-Sep
Fondée en 2015 à Nantes, i-SEP est une medtech spécialisée dans l'autotransfusion peropératoire et la gestion du sang des patients. Chez i-SEP, nous avons développé, breveté et commercialisons désormais une technologie innovante de récupération et de séparation des composants sanguins. En collaboration avec nos cliniciens, nous développons des solutions uniques de gestion du sang des patients pour améliorer les avantages pour les patients et les parties prenantes. Nous travaillons en étroite collaboration avec des cliniciens spécialisés dans le but d’améliorer les avantages pour les patients, de simplifier le flux de travail des médecins et de contribuer à réduire les coûts des soins de santé. Notre innovation apporte une valeur ajoutée significative par rapport aux solutions actuellement disponibles, notamment en termes de qualité du sang. i-SEP a été co-fondée par trois associés : Dr Francis Gadrat, médecin anesthésiste, Bertrand Chastenet, ancien chef d’entreprise et consultant dans l'industrie pharmaceutique, conseiller du commerce extérieur de la France, et Sylvain Picot, fondateur de Biom’Up. i-SEP est accompagnée par Atlanpole et membre du pôle de compétitivité Atlanpole Biothérapies- Founded in 2015 in Nantes (Upper Britany, France), i-SEP is a medtech specialized in intraoperative autotransfusion and Patient Blood Management. At i-SEP, we have developed, patented and now markets an innovative technology for the recovery and separation of blood components. Together with our clinicians, we develop unique Patient Blood Management solutions for improved patient & stakeholder benefits. We work closely with specialized clinicians with the aim of improving patient benefits, simplifying physicians’ workflow and helping reduce healthcare cost. Our innovation brings significant added value compared to currently available solutions, particularly in terms of blood quality.
11 to 50 staff
Innovative Diagnostics
Since 2004, Innovative Diagnostics (ID) develops, produces and sells ELISA, PCR and rapid tests to diagnose infectious zoonotic and veterinary diseases. Over 130 employees work in our m² headquarters at the heart of the “MED Valley” of Montpellier, France. ID has shown continuous growth over the years and offers a wide range of veterinary tests sold in over 100 countries under the brand name IDvet. ID is an actor of the One Health approach, which recognizes that human and animal health are interdependent. We contribute to securing the global health and food supply, thanks to the control of zoonotic and veterinary diseases. Further to the emergence of COVID-19, we quickly developed COVID-19 ELISA tests detecting IgG, IgA and IgM in sera, and an immunochromatographic test for nasopharyngeal swabs. “With you at every step” is our motto. To improve global supply and assistance, we have a training center in Jordan, offices in Brazil, India, China, and a production facility in the USA. In 2016, we contributed to creating ID Solutions to provide tools to detect oncogenic mutations in human circulating DNA by dPCR. When COVID-19 emerged, ID made its know-how, industrial infrastructures, staff and financial resources available to ID Solutions in order to develop and produce COVID-19 PCR kits for use in humans, allowing ID Solutions to become a major COVID PCR kit manufacturer in France. ID left ID Solutions presidency in December 2021 and sold all its shares in May 2022. ID Solutions is now fully independent and heading for their new own projects. In 2021, ID contributed to the creation of DI4diag: “Deep Intelligence for diagnostics”. This company gathers talents from Montpellier University and the industry. It aims to provide easy-to-use and affordable diagnostics for syndromic infectious diseases, thanks to technologies that combine molecular technics and artificial intelligence. These testing tools will be particularly useful for LMIC.
51 to 200 staff
Netri
NETRI is an Techbio industrial start-up whose mission is to improve human health through the discriminating power of the nervous system. The company offers a Neuron-as-a-sensor suite (NaaS) to gain insights into the safety and efficacy of clinical or chemical compounds. NETRI focuses on pain quantification and pursues an exploratory pipeline in oncology-related adverse events, dermo-cosmetics, neurological disorders and neurotoxicity. Leveraging the natural capacity of neurons to encode biological interactions into electrical impulses, the NaaS suite features the world-first compartmentalized electrophysiology platform in standard 96-well plate format - NeuroFluidics™ MEA - which acts as a data generation hub for its digital signature libraries of tested and reference compounds. To enable the prediction of clinical outcomes, the proprietary suite includes calibrated neuronal cells, Organ-on-chip hardware, AI-trained software, digital libraries and methods.
11 to 50 staff
Osivax
Osivax is a clinical-stage biopharmaceutical company developing a portfolio of differentiated influenza vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses, thanks to its novel, self-assembling nanoparticle platform technology, oligoDOMTM. The company’s lead candidate, OVX836, is a broad-spectrum influenza A vaccine candidate currently in Phase 2b clinical trials with over volunteers tested and encouraging efficacy proof of concept data. By combining OVX836 with standard flu vaccines, Osivax is advancing toward a best-in-class seasonal flu vaccine to prevent all strains of influenza. Osivax collaborates with leading global health agencies and top-tier pharmaceutical companies, reinforcing its mission to prevent all types of seasonal and pandemic influenza. The company will expand into other infectious disease indications through combinations and collaborations worldwide.
11 to 50 staff
Sartorius Stedim Biotech
A profile of Sartorius Stedim Biotech Leading Partner Sartorius Stedim Biotech is a leading partner of the biopharma industry. Our solutions are supporting our customers to produce drugs safely, timely and economically. The key product categories of our company are cell cultivation, fermentation, filtration, purification, and fluid management. Global Presence Sartorius Stedim Biotech has a worldwide presence, with manufacturing, sales and R&D sites in more than 20 countries in Europe, North America and Asia. More than employees across the globe focus on single-use technologies and added-value services to meet the rapidly changing technology requirements of the industry it serves. If you are interested in careers at Sartorius, please take a look at our career page:
5001 to 10000 staff
Shimadzu France
Expert reconnu dans le domaine des solutions analytiques complètes – couvrant la médecine, la chimie, la pharmacie, l’agroalimentaire et l’environnement – Shimadzu figure parmi les leaders mondiaux de l’instrumentation scientifique. Depuis 1875, notre philosophie est claire : mettre notre expertise au service de la science. Créée en 2002, la filiale française de Shimadzu s’appuie sur l’innovation technologique de Shimadzu Corporation tout en développant localement des solutions adaptées aux besoins des laboratoires. Notre équipe d’ingénieurs d’applications conçoit des solutions analytiques complètes, fiables et éprouvées, permettant aux laboratoires d’optimiser leurs performances. Shimadzu accompagne vos équipes pour répondre aux exigences réglementaires et aux standards de qualité de la production, tout en relevant les défis analytiques les plus complexes. Notre mission : fournir des outils et un savoir-faire qui facilitent vos analyses, garantissent la précision de vos résultats et stimulent l’innovation dans vos laboratoires.
51 to 200 staff
Standard Biotools
Standard BioTools delivers the leading proteomic and multi-omic solutions that enable researchers to discover unique biological insights not accessible by other technologies.
501 to 1000 staff
Animine
Animine is a global supplier of value-added sources of trace elements for animal nutrition.
11 to 50 staff
Aqemia
AQEMIA is a drug invention company dedicated to novel medicines — never me-toos — tackling major diseases such as oncology. Our physics-based, generative AI platform invents drug candidates beyond the reach of traditional R&D, without dependence on experimental data. We are building a rapidly expanding portfolio of proprietary programs, alongside collaborations with top pharmaceutical companies. Multiple discovery successes are already achieved, with lead programs progressing through in vivo optimization. AQEMIA is part of the French Tech 120 program, which supports the most promising scale-ups in France with global impact potential. AQEMIA is member of the BioIndustry Association (BIA) and the Knowledge Quarter in London. AQEMIA is based in Paris (HQ) and London. We are growing and hiring! Discover our opportunities here: https://jobs.lever.co/aqemia.com Discover the roles and behind-the-scenes at AQEMIA:
51 to 200 staff
Aryballe
Aryballe combines biochemistry, advanced optics and machine learning to mimic the human sense of smell. Aryballe’s unique software and data solutions provide odor display and analysis that helps leaders in the automotive, food & beverage, consumer appliance and flavor & fragrance industries make smarter and more informed business decisions. In addition, Aryballe's digital olfaction solutions help companies improve user experiences with applications in the automotive and consumer appliance markets. The company is headquartered in France and with commercial operations in the USA and Korea.
51 to 200 staff
Bforcure
To be more responsive, more efficient and make better decisions, BforCure allows public and industrial stakeholders to access biological information in real time, thanks to an innovative technology of rapid biodetection.
51 to 200 staff
Biowest
Biowest SAS (Biowest) is the European leader in the collection and processing of animal sera and cell culture media, offering the widest range of sera and media available on the market. Biowest controls the production of the sera throughout the entire process, from collections around the world to final shipment of bottled serum from its warehouse. Biowest offers standard cell culture media as well as custom-made formulations for specific applications, using its outstanding knowledge of cell culture products. Biowest can also offer highest quality and premium service, ability to address special requirements and full traceability and security guaranteed by vertical integration. Founded in 1987, Biowest has since 2004 been a member of the Viking/Serascandia group, collectors of animal by-products in Latin America; thus becoming the first serum company vertically integrated from raw material to finished product.
11 to 50 staff
Cepheid
Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid’s broad test portfolio spans respiratory infections, blood virology, women’s and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company’s solutions deliver actionable results where they are needed most – from central laboratories and hospitals to near-patient settings. For more information, visit Cepheid is proud to be a part of Danaher. Danaher’s science and technology leadership puts Cepheid’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics, and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.
5001 to 10000 staff
